Navidea Biopharmaceuticals Announces Participation in Alzheimer’s Disease Scientific Meetings

Dr. Thomas Tulip presents overview of β-Amyloid imaging biomarker, AZD4694, development

DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE Amex: NAVB), a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that Dr. Thomas Tulip, Navidea’s EVP and Chief Business Officer, was invited to present at two Alzheimer’s Disease (AD) conferences: Alzheimer’s Disease Neuroimaging Initiative (ADNI) Private Partner Scientific Board meeting and the German Nuclear Medicine Convention. Focused on Navidea’s AZD4694 radiopharmaceutical imaging biomarker for the detection of cerebral amyloid in Alzheimer’s disease (AD) patients, Dr. Tulip’s presentations highlighted AZD4694 background, status and strong attributes, such as high sensitivity and low non-target accumulation. These and other characteristics of the agent appear to make it an excellent candidate as a biomarker to facilitate enhanced therapeutic drug development.

The ADNI meeting was held on April 22, 2012 in New Orleans, LA in conjunction with this year’s American Academy of Neurology convention and brings together scientists from academia, government and the private sector to discuss the progress in the field of AD research. The goal of ADNI, which is funded by the National Institutes of Health (NIH) and a consortium of pharmaceutical companies, is to define the rate of progress of Alzheimer's disease, to develop improved methods for clinical trials in this area, and to provide a large database which will improve design of treatment trials. The ADNI study is following the rate of change of cognition, function, brain structure and function, and biomarkers in elderly controls, subjects with mild cognitive impairment, and those diagnosed with AD.

The German Nuclear Medicine Convention is being held April 25-28, 2012 in Bremen, Germany. Dr. Tulip’s presentation entitled “AZD4694: A Highly Sensitive 2nd Generation Aβ Biomarker” will be held on April 26th in the New Tracers for Amyloid-Imaging in a Clinical Setting session.

About AZD4694

AZD4694 is a Fluorine-18 labeled precision radiopharmaceutical candidate for use in the imaging and evaluation of patients with signs or symptoms of cognitive impairment such as AD. It binds to Beta-amyloid deposits in the brain that can then be imaged in positron emission tomography (PET) scans. Amyloid plaque pathology is a required feature of AD diagnosis and the presence of amyloid pathology is a supportive feature for diagnosis of probable AD.

About Navidea Biopharmaceuticals, Inc.

Navidea Biopharmaceuticals, Inc. (NYSE Amex: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing three radiopharmaceutical agent platforms – Lymphoseek®, AZD4694 and RIGScanTM – to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and ultimately patient care. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company’s pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit

Navidea Biopharmaceuticals, Inc.
Brent Larson, 614-822-2330
Sr. VP & CFO

Source: Navidea Biopharmaceuticals, Inc.